These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26209894)

  • 1. Eosinophilia in Hematologic Disorders.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
    Gotlib J
    Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hematological disorders and hypereosinophilias].
    Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
    Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
    Kjeldsen E
    Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
    Gotlib J
    Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
    Savage N; George TI; Gotlib J
    Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
    Chalmers ZR; Ali SM; Ohgami RS; Campregher PV; Frampton GM; Yelensky R; Elvin JA; Palma NA; Erlich R; Vergilio JA; Chmielecki J; Ross JS; Stephens PJ; Hermann R; Miller VA; Miles CR
    Blood Cancer J; 2015 Feb; 5(2):e278. PubMed ID: 25658984
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
    Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
    Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modern diagnosis and treatment of primary eosinophilia.
    Tefferi A
    Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1].
    Fan XS; Wang SA
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):779-83. PubMed ID: 23302345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.